Skip to content

Study · Non-randomized trial · n = 18 · 2013

2 results

[Assessment of the size of the thalamus as a method for the evaluation of the activity of neurodegenerative process after the treatment with cerebrolisin in young patients with multiple sclerosis].

Boĭko AN, Batysheva TT, Mel'nikova MV, Boĭko OV, Mugutdinova BT, Gorina TP, Ovcharov VV, Bykova OV, Popova NF, Gusev EI

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2013Cited by 2 (Europe PMC)

PMID23528602 (opens in a new tab)PepBankPUB-23528602
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In young patients with active relapsing multiple sclerosis, thalamic atrophy decreased after Cerebrolysin treatment.

    In plain wordsIn young multiple sclerosis patients, thalamic atrophy decreased after Cerebrolysin treatment compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseThalamic atrophy
    Study

    n = 18

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After treatment with cerebrolysin, there was the decrease in the level of atrophy that suggested the neuroprotective effect of this drug.
    2 context sentences
    Summary · context
    Eighteen MS patients (mean age 20.10±0.45 years) with disease onset in childhood or adolescence were studied.
    Summary · context
    Neurological examination using the EDSS, neuropsychological testing and MRI were used.
  2. 02HumanNon-randomized trialEfficacy outcome

    In multiple sclerosis patients, the reduction in thalamic atrophy after Cerebrolysin was more prominent in younger patients with frequent previous relapses.

    In plain wordsIn multiple sclerosis patients, the atrophy reduction after Cerebrolysin was greater in younger patients with frequent previous relapses.

    Peptide
    Cerebrolysin
    Outcome
    Not applicableThalamic atrophy treatment effect by patient characteristics
    Study

    n: not reported in source

    Comparator
    Other studied patients
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This effect was more prominent in younger patients with the high frequency of previous relapses.
    3 context sentences
    Summary · context
    After treatment with cerebrolysin, there was the decrease in the level of atrophy that suggested the neuroprotective effect of this drug.
    Summary · context
    Eighteen MS patients (mean age 20.10±0.45 years) with disease onset in childhood or adolescence were studied.
    Summary · context
    Neurological examination using the EDSS, neuropsychological testing and MRI were used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.